Faron (FARN.L): Data from Phase 1/2 MATINS trial – from yesterday | Arix Bioscience (ARIX.L): Antibiotic portfolio company narrowly misses endpoint in Phase 3 trial – from yesterday
12 Dec 2019
SP Angel Healthcare Conditions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare Conditions
- Published:
12 Dec 2019 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
3
Faron (FARN.L): Data from Phase 1/2 MATINS trial – from yesterday | Arix Bioscience (ARIX.L): Antibiotic portfolio company narrowly misses endpoint in Phase 3 trial – from yesterday